Paul C Reilly

US Patent:

20060222640, Oct 5, 2006

Filed:

Mar 26, 2006

Appl. No.:

11/277503

Inventors:

Paul Reilly - Danbury CT, US
James Gilbert - Bethlehem CT, US
Thomas Mueller - Danbury CT, US

Assignee:

Boehringer Ingelheim International GmbH - Ingelheim

International Classification:

A61K 38/48
A61K 31/727
A61K 31/4439

US Classification:

424094640, 514338000, 514056000

Abstract:

The present invention relates to novel pharmaceutical compositions comprising at least one direct thrombin inhibitor and at least one additional active compound selected from the groups consisting of platelet inhibitors, low molecular weight heparins (LMWH) and heparinoids as well as unfractionated heparin, factor Xinhibitors, combined thrombin/factor Xinhibitors, fibrinogen receptor antagonists (glycolprotein IIb/IIa antagonists) and Vitamin K antagonists, optionally together with one or more pharmaceutically acceptable excipients or carriers for the treatment of thrombosis.

US Patent:

20080039391, Feb 14, 2008

Filed:

Jul 17, 2007

Appl. No.:

11/779029

Inventors:

Andreas Clemens - Wiesbaden, DE
Paul Reilly - Ridgefield CT, US
Bernd Plohmann - Schemmerhofen, DE

Assignee:

Boehringer Ingelheim International GmbH - Ingelheim

International Classification:

A61K 31/4439
A61K 31/397
A61K 31/4709
A61K 38/17
A61P 9/00

US Classification:

514012000, 514210170, 514314000, 514338000

Abstract:

The invention relates to new indications for direct thrombin inhibitors such as dabigatran etexilate in the cardiovascular field.

US Patent:

20080200514, Aug 21, 2008

Filed:

Jul 17, 2007

Appl. No.:

11/778748

Inventors:

Andreas Clemens - Wiesbaden, DE
Paul A. Reilly - Ridgefield CT, US

Assignee:

Boehringer Ingelheim International GmbH - Ingelheim

International Classification:

A61K 31/4439
A61P 25/28

US Classification:

514338

Abstract:

The invention relates to new indications for direct thrombin inhibitors such as dabigatran etexilate in the CNS and other fields.

US Patent:

20100173947, Jul 8, 2010

Filed:

Mar 22, 2010

Appl. No.:

12/728732

Inventors:

Andreas Clemens - Wiesbaden, DE
Paul A. Reilly - Ridgefield CT, US

Assignee:

Boehringer Ingelheim International GmbH - Ingelheim

International Classification:

A61K 31/4439
A61K 31/4709
A61K 38/17
A61K 31/397
A61K 31/4184
A61P 35/00
A61P 25/28
A61P 29/00
A61P 13/12
A61P 7/02

US Classification:

514338, 514314, 514 12, 51421017, 514394

Abstract:

The invention relates to new indications for direct thrombin inhibitors such as dabigatran etexilate in the CNS and other fields.

US Patent:

20100184729, Jul 22, 2010

Filed:

Mar 19, 2010

Appl. No.:

12/727933

Inventors:

Paul A. Reilly - Danbury CT, US
James C. Gilbert - Bethlehem CT, US
Thomas H. Mueller - Danbury CT, US

Assignee:

Boehringer Ingelheim International GmbH - Ingelheim

International Classification:

A61K 31/616
A61K 31/4365
A61P 7/02
A61P 9/10

US Classification:

514161, 514301

Abstract:

The present invention relates to novel pharmaceutical compositions comprising at least one direct thrombin inhibitor and at least one additional active compound selected from the groups consisting of platelet inhibitors, low molecular weight heparins (LMWH) and heparinoids as well as unfractionated heparin, factor Xinhibitors, combined thrombin/factor Xinhibitors, fibrinogen receptor antagonists (glycolprotein IIb/IIa antagonists) and Vitamin K antagonists, optionally together with one or more pharmaceutically acceptable excipients or carriers for the treatment of thrombosis.

US Patent:

20100322869, Dec 23, 2010

Filed:

Jun 17, 2010

Appl. No.:

12/817347

Inventors:

Paul Anthony REILLY - Danbury CT, US

Assignee:

BOEHRINGER INGELHEIM INTERNATIONAL GMBH - Ingelheim am Rhine

International Classification:

A61K 31/4439
A61K 49/00
A61P 7/02
A61P 9/00

US Classification:

424 103, 514338

Abstract:

A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

US Patent:

20100322870, Dec 23, 2010

Filed:

Jun 17, 2010

Appl. No.:

12/817369

Inventors:

Paul Anthony REILLY - Danbury CT, US

Assignee:

BOEHRINGER INGELHEIM INTERNATIONAL GMBH - Ingelheim

International Classification:

A61K 31/4439
A61K 49/00
A61P 7/02
A61P 9/06
A61P 9/10
A61P 9/00

US Classification:

424 103, 514338

Abstract:

A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

US Patent:

20110251160, Oct 13, 2011

Filed:

Nov 10, 2009

Appl. No.:

13/128463

Inventors:

Paul Anthony Reilly - Danbury CT, US

Assignee:

BOEHRINGER INGELHEIM INTERNATIONAL GMBH - Ingelheim

International Classification:

A61K 31/443
A61K 31/4709
C07D 401/12
A61K 31/616
A61P 9/10
A61P 7/02

US Classification:

514161, 514338, 5462734, 514305

Abstract:

A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient a dosage of >150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.